Michigan’s only health system taking part in multicenter, multinational study to help prevent recurrence of breast cancer
Researchers at Beaumont Health System are seeking volunteers for a clinical research study to test a vaccine to prevent recurrence of early stage breast cancer. Study candidates include those with low to moderate amounts of the “Human Epidermal Growth Factor Receptor 2” protein, commonly referred to as HER2.
HER2 is found in breast cancer cells in large amounts about 20 to 30 percent of the time and in low to moderate amounts about 60 to 70 percent of the time.
Beaumont is the only health system in Michigan participating in the study, according to the National Cancer Institute and Galena Biopharma Inc., the sponsor funding this research.
Women, age 18 and older, who have or have had breast cancer and have completed treatment for early stage breast cancer may be eligible to participate.
At least 700 patients will take part in the study at about 150 sites in the United States and other countries, with approximately 10 patients from Beaumont Health System expected to be included. Long-term follow-up for the study is expected to last approximately 10 years.
“The early studies of the NeuVax vaccine in women with breast cancer have shown a decrease in the recurrence of cancers with weak HER2/neu expression,” explains the study’s Principal Investigator Laura Nadeau, M.D., hematology and oncology specialist at Beaumont Hospital, Royal Oak. “This study involves the mixing of an existing FDA-approved drug that stimulates the immune system with the new drug called NeuVax. The combined experimental vaccine will be used to help collect information and show its effectiveness,” she explains.
For more information, including questions on eligibility, call Beaumont’s Cancer Clinical Trial Office at 248-551-7695, or search for “NCT01479244” at www.clinicaltrials.gov.
Breast cancer is the second most common cancer among American women. The American Cancer Society estimates that more than 230,000 new cases of invasive breast cancer will be diagnosed in women; and 62,000 new cases of noninvasive cancer, which is the earlier form of breast cancer, will be diagnosed this year.
About Beaumont’s Cancer Program
Beaumont’s comprehensive cancer program combines the expertise of surgical, medical and radiation oncologists to offer cancer prevention counseling, diagnosis and treatment in hospital and community-based settings. The Beaumont Cancer Institute is one of only 49 Community Clinical Oncology Programs in the country designated by the National Cancer Institute to provide patients with access to leading-edge cancer clinical research trials. Beaumont is designated as a Blue Cross Center of Distinction for the Treatment of Rare and Complex Cancers. Beaumont, Royal Oak and Troy are recognized by U.S. News & World Report as “high performing” hospitals for cancer care. Find out more at http://cancer.beaumont.edu/.